ArticlePloS one2010
A prospective study of aspirin use and the risk of gastrointestinal bleeding in men.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Pooled it
- Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies.PloS one · 2016Pooled it
- Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population.European journal of epidemiology · 2015Pooled it
- Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis.PloS one · 2013Pooled it
- Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double-Blind, Placebo-Controlled Study Proposal.Laryngoscope investigative otolaryngology · 2025Review
- Article
- Molecular Ultrasound Imaging Depicts the Modulation of Tumor Angiogenesis by Acetylsalicylic Acid.International journal of molecular sciences · 2023Article
- Bioactivity-boosting strategy based on combination of anti-allergic O-methylated catechin with a Citrus flavanone, hesperetin.Journal of natural medicines · 2023Article
- Incidence and outcome of gastrointestinal bleeding in patients receiving aspirin with or without clopidogrel over 10 years- An observational study.Journal of family medicine and primary care · 2022Article
- Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review.International journal of general medicine · 2021Review
- Low-dose aspirin and risk of upper/lower gastrointestinal bleeding by bleed severity: a cohort study with nested case-control analysis using primary care electronic health records from the United Kingdom.Annals of medicine · 2019Article
- Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting.Journal of managed care & specialty pharmacy · 2018Article
- A Pharmacoepidemiology Database System for Monitoring Risk Due to the Use of Medicines by New Zealand Primary Care Patients.Drug safety · 2017Article
- A Prospective Study of Alcohol Consumption and Smoking and the Risk of Major Gastrointestinal Bleeding in Men.PloS one · 2016Article
- Venous thromboprophylaxis in gastrointestinal bleeding.Canadian journal of gastroenterology & hepatology · 2015Article
- Measures of adiposity are associated with increased risk of peptic ulcer.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2014Article
- Role of aspirin in cancer prevention.Current oncology reports · 2013Review
- Management of lower gastrointestinal bleeding in older adults.Drugs & aging · 2012Review
- Aspirin in the chemoprevention of colorectal neoplasia: an overview.Cancer prevention research (Philadelphia, Pa.) · 2012Review
- Aspirin for the prevention of colorectal cancer.Best practice & research. Clinical gastroenterology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsData regarding the influence of dose and duration of aspirin use on risk of gastrointestinal bleeding are conflicting.
methodsWe conducted a prospective cohort study of 32,989 men enrolled in the Health Professionals Follow-up Study (HPFS) in 1994 who provided biennial aspirin data. We estimated relative risk of major gastrointestinal bleeding requiring hospitalization or a blood transfusion.
resultsDuring 14 years of follow-up, 707 men reported an episode of major gastrointestinal bleeding over 377,231 person-years. After adjusting for risk factors, regular aspirin use (≥2 times/week) had a multivariate relative risk (RR) of gastrointestinal bleeding of 1.32 (95% confidence interval [CI], 1.12-1.55) compared to non-regular use. The association was particularly evident for upper gastrointestinal bleeding (multivariate RR, 1.49; 95% CI, 1.16-1.92). Compared to men who denied any aspirin use, multivariate RRs of upper gastrointestinal bleeding were 1.05 (95% CI 0.71-1.52) for men who used 0.5-1.5 standard tablets/week, 1.31 (95% CI 0.88-1.95) for 2-5 aspirin/week, 1.63 (95% CI, 1.15-2.32) for 6-14 aspirin/week and 2.40 (95% CI, 1.10-5.22) for >14 aspirin/week (P(trend)<0.001). The relative risk also appeared to be dose-dependent among short-term users <5 years; P(trend)<.001) and long-term users (≥5 years; P(trend) = 0.015). In contrast, after controlling for dose, increasing duration of use did not appear to be associated with risk (P(trend) = 0.749).
conclusionsRegular aspirin use increases the risk of gastrointestinal bleeding, especially from the upper tract. However, risk of bleeding appears to be more strongly related to dose than to duration of use. Risk of bleeding should be minimized by using the lowest effective dose among short-term and long-term aspirin users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.